ViiV Healthcare's EMBRACE study shows VH109 with CAB LA effectively suppresses HIV. The company also reports promising early ...

GSK (GSK) announced that ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer (PFE) and Shionogi (SGIOY) as ...

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today ...

Lytho, a leading provider of creative workflow solutions, is proud to announce its inclusion in G2's 2025 Best ...

ViiV Healthcare, majority owned by GSK (GSK), with Pfizer (PFE) (PE) and Shionogi as shareholders, announced findings from the company’s ...

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced positive findings from the company’s EMBRACE phase IIb study.1 The ...

GSK’s ViiV Healthcare has shared clinical data on three potential long-acting HIV treatments, providing a look at how its ...

February is the shortest month, but there was still plenty of time for a rush of pharma and biotech hires, including a number ...

• In February 2025, AbbVie announced that the FDA had approved Emblaveo (aztreonam and avibactam) in combination with ...

Antibiotic-resistant bacteria are one of the greatest health threats of our age – but there are plans to beat them ...

The change in leadership comes shortly after Indivior warned that it is expecting a sharp decline in its revenues in 2025, ...

Ciaffoni was appointed as a nonexecutive director of Indivior in December, and previously served as President and CEO of Collegium Pharmaceutical. Prior to that, he held senior roles at Endo ...